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Objectives: The International Registry of Lung Metastases was established 
in 1991 to assess the long-term results of pulmonary lnetastasectomy. Methods: 
The Registry has accrued 5206 cases of lung metastasectomy, from 18 
departments of thoracic surgery in Europe (n = 13), the United States (n = 4) 
and Canada (n = 1). Of these patients, 4572 (88%) underwent complete 
surgical resection. The primary tumor was epithelial in 2260 cases, sarcoma in 
2173, germ cell in 363, and melanoma in 328. The disease-free interval was 0 
to 11 months in 2199 cases, 12 to 35 months in 1857, and more than 36 months 
in 1620. Single metastases accounted for 2383 cases and multiple lesions for 
2726. Mean follow-up was 46 months. Analysis was performed by Kaplan- 
Meier estimates of survival, relative risks of death, and multivariate Cox 
model. Results: The actuarial survival after complete metastasectomy was 36% 
at 5 years, 26% at 10 years, and 22% at 15 years (median 35 months); the 
corresponding values for incomplete resection were 113% at 5 years and 7% at 
10 years (median 15 months). Among complete resections, the 5-year survival 
was 33% for patients with a disease-free interval of 0 to 11 months and 45% for 
those with a disease-free interval of more than 36 months; 43% for single 
lesions and 27% for four or more lesions. Multivariate analysis showed a better 
prognosis for patients with germ cell tumors, disease-free intervals of 36 
months or more, and single metastases. Conclusions: These results confirm 
that lung metastasectomy is a safe and potentially curative procedure. Resect- 
ability, disease-free interval, and number of metastases enabled us to design a 
simple system of classification valid for different tumor types. (J Thorac 
Cardiovasc Surg 1997;113:37-49) 
S urgical resection of pulmonary metastases is now 
considered a standard therapeutic procedure in 
properly selected cases and is routinely performed 
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in many departments of thoracic surgery. In fact, 
many tumors may involve the lung as the unique site 
of distant spread. Complete surgical excision f all 
pulmonary deposits is often technically feasible with 
low morbidity and mortality) -3
However, the curative potential of metastasec- 
tomy had been recognized slowly. Pulmonary me- 
tastasectomy has been gradually accepted as a sur- 
gical procedure of proved therapeutic value in 
selected cases. Several years after the first resection 
of a single lung metastasis, discovered uring the 
excision of a chest wall sarcoma, 4 elective surgery 
has been occasionally offered to selected patients 5 
with single pulmonary metastases or a long disease- 
free interval (DFI). 6 In only a few selected centers 
has metastasectomy been applied systematically to
multiple or bilateral esions, with the hope of im- 
proving long-term survival. 7' 8 In addition, adjuvant 
chemotherapy has also been used to facilitate surgi- 
cal resection. 
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Although the criteria of eligibility have been 
progressively expanded, it is dilIicult to assess the 
real proportion of patients with isolated lung metas- 
tases who are candidates for salvage surgery, be- 
cause the denominator cannot be properly defined 
in most clinical conditions. In some tumors, such as 
sarcomas, germ cell tumors, or pediatric malignant 
tumors, a high proportion (>50%) of all patients 
with lung metastases may be candidates for metas- 
tasectomy. 9 However, in most epithelial cancers 
only a small minority of patients with distant disease 
may be considered. 
The data so rar available suggest hat lung metas- 
tasectomy is able to improve significantly the overall 
and disease-free survival with a limited morbidity 
and mortality. The overall 5-year survival ranges 
between 20% and 40% when all the primary sites 
are combined, 1'2 much higher than expected after 
chemotherapy or radiotherapy alone. 1°-12 
Unfortunately, the majority of the experiences 
reported in the literature are affected by small 
numbers and limited follow-up. Even in the largest 
series it is difficult to adjust properly for the heter- 
ogeneity of patients in terms of age, sex, primary 
tumor type, extent of metastatic spread, surgical 
techniques, and concurrent medical treatments. 13-16 
Major areas of controversy remain with respect o 
the following aspects: selection of patients (i.e., 
maximum number of resectable metastases), bilat- 
eral surgical staging, adjuvant chemotherapy, and 
prognostic factors for each primary tumor 
site.S, 14, 17 
For all these reasons it appeared reasonable to try 
to overcome the limits of present knowledge by a 
cooperative multicentric linical study. The Interna- 
tional Registry of Lung Metastases was launched in 
1990 with a few clear objectives: set up a common 
database through the major centers of thoracic 
surgery in Europe and the United States to facilitate 
the exchange of information; perform a more ho- 
mogeneous evaluation of the results for the various 
primary tumors; define prognostic factors by multi- 
variate analysis; propose a novel system of stage 
grouping; and define areas of uncertainty concern- 
ing surgery and other therapeutic modalities to be 
explored by prospective randomized trials. 
This article is the first analysis of the data col- 
lected by the International Registry. 
Patients and methods 
Structure of the database. A new comprehensive data- 
base was designed at the Istituto Nazionale Tumori of 
Milan to provide a simple and flexible instrument for the 
Registry. This included a single record form for each 
patient, divided into four different sections: identiflcation 
of patients, description of the primary neoplasm (time, 
site, histology, type of therapy), description of every 
metastasectomy performed (date, number and size of 
deposits, type of operation, and combined therapies), and 
the updated follow-up (pulmonary recurrence, relapse in 
other organs, treatment, and outcome). All data (except 
identification of patients) were precoded; in addition, 
extended escription was requested for the primary site, 
histologic type, and concurrent nonpulmonary esections. 
Patients who underwent planned sequential or staged 
thoracotomies were considered to have had one single 
metastasectomy and not redo surgery. All major centers of 
thoracic surgery with a specific experience in the surgical 
management of lung metastases were contacted and of- 
fered the opportunity to join the Registry. Speciflc soft- 
ware programs were designed to retrieve the information 
already available in the various centers, by computerized 
recoding and import in the new database, and to update 
the patients' follow-up. 
Aeerual of patients. All patients who underwent resec- 
tion of lung metastases (metastasectomy) with curative 
intent were considered eligible for the Registry. Incom- 
plete ablation of pulmonary metastases, although not 
necessarily ä reason for exclusion, had to be unequivocally 
identified. Eradication of the primary tumor and absence 
or effective treatment of metastases in other organs, 
before or concurrent with pulmonary metastasectomy, 
were considered mandatory for inclusion in the Registry. 
The acerual of patients in the database was activated in 
1991. A pilot study was performed with the use of the data 
available at the Istituto Nazionale Tumori of Milan and at 
the Royal Brompton Hospital of London. All records 
derived from the other centers were subsequently merged 
by means of purpose-designed recodification systems for 
each original source of data. For those centers in which a 
local database was not available, a copy of the Registry 
database was delivered to allow the input of data on site. 
One or more site visits were necessary in some centers 
to help with the data collection, retrieve missing informa- 
tion, and update the follow-up. The medical research 
fellows participating in the data management visited eight 
centers in five countries, spending a total of 14 man- 
months abroad. 
From 1991 to 1995, 5290 patients were enrolled in the 
International Database, covering a period of more than 
four decades. In fact, the first metastasectomy was per- 
formed in 1945. Adequate information was available for 
the vast majority of these patients. Only 84 (1.6%) were 
excluded from the present analysis because of missing 
crucial information such as age, sex, site of primary tumor, 
type of primary tumor, or number of resected metastases. 
A further small group of 46 patients were not included in 
the multivariate analysis of complete resections because 
of other missing information. 
The distribution of the 5206 eligible patients among the 
18 members of the Registry is illustrated in the appendix. 
Analysis. The data were analyzed by an independent 
agency (Institute of Drug Development, or ID2, Brussels) 
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using the SAS Statistical Analysis System under license 
from the SAS Institute (Cary, N.C.). 
The following variables were tested: sex, age, number of 
resected as well as pathologically proved metastases, DFI, 
and histologic type and site of the primary tumor. For the 
multivariate analysis, primary histology codes were 
grouped as follows: breast, lung, bowel, kidney, uterus, 
and head and neck cancer, osteosarcoma, other bone 
sarcomas, histiocytoma, leiomyosarcoma, synovial sar- 
coma, other soft tissue sarcomas, Wilms' tumor, teratoma, 
embryonal carcinoma, other germ cell tumors, and any 
other tumors. 
Survival was calculated from the time of first metasta- 
sectomy to the last date of follow-up by means of the 
Kaplan-Meier estimate and the log-rank test. 
So that variables could be screened for their potential 
prognostic value, the patients in each level of a variable 
were contrasted with the rest of the patient population. 
The hazard rate for each level of the variable relative to 
the rest of the population (called for simplicity the 
"relative risk of death") was estimated, together with its 
95% confidence limits, via a Cox proportional hazard 
model. A relative risk of death smaller than 1 indicated a
better than average prognosis. All variables with signifi- 
cant prognostic impact on survival were submitted simul- 
taneously to a Cox regression model. 
Results 
Patients' features. A total of 5206 cases of lung 
metastasectomy were included in the present anal- 
ysis, of which 4572 (88%) involved eomplete surgical 
resection. Metastasectomy was considered incom- 
plete in 634 patients (12%) because of microscopic 
(n = 127) or macroseopie (n = 507) residual disease. 
Main patient features are shown in Table I ac- 
cording to the completeness of resection. Overall, 
2932 (56%) were male and mean age was 44 years 
(median 46 years, range 2 to 93 years). 
In 43% of patients lung metastases were from an 
epithelial tumor, in 42% from sareomas, in 7% from 
germ cell tumors, in 6% from melanomas, and in 2% 
from other types, ineluding 30 ¢ases of Wilms' 
tumors. In the whole series, 31% of patients had a 
DFI  of 0 to 11 months, including 11% who had 
synchronous metastases; 36% had a DFI  of 12 to 35 
months and 31% of 36 months or more. Median 
DFI  was 19 months. In most patients (64%) with 
germ cell tumors the DFI  was less than 12 months; 
the corresponding value was 39% for sarcomas, 21% 
for epithelial tumors, and 17% for melanomas. In 
126 (2%) patients the DFI  was not speeified. 
The surgical approaeh was monolateral thoracot- 
omy in 58% of patients, bilateral syn¢hronous or 
staged thoracotomy in 11%, median sternotomy in 
27%, and thoracoscopy in only 2%. For the large 
majority of patients the maximum resection volume 
Table I. Patients'features 
Complete Incomplete Total 
Age (yr): 
Mean (range) 44 (2-93) 43 (2-79) 44 (2-93) 
Sex 
Male 2587 345 2932 
Female 1984 289 2273 
Type 
Epithelial 1984 276 2260 
Sarcoma 1917 256 2173 
Germ cell 318 45 363 
Melanoma 282 46 328 
Other 70 11 81 
Free interval 
0 469 87 556 
1-11 mo 915 132 1047 
12-35 mo 1662 195 1857 
36+ mo 1416 204 1620 
Approach 
Monolateral 2770 341 3111 
thoracotomy 
Bilateral 534 42 576 
thoracotomy 
Sternotomy 1179 236 1415 
Thoraeoscopy 84 9 93 
Resection 
Wedge 3012 461 3473 
Segment 409 40 449 
Lobe 1014 95 1109 
Pneumonectomy 112 21 133 
Other resections 344 102 446 
Number 
1 2169 214 2383 
2-3 1226 147 1373 
4+ 1123 230 1353 
Diseased nodes 174 65 239 
(N1-2) 
Chemotherapy 
Preoperative 932 213 1145 
Postoperative 698 143 841 
Redo surgery 
2 operations 732 54 786 
>- 3 operations 243 13 256 
Total 4572 634 5206 
was sublobar, including 67% wedge resections, 9% 
segmentectomies, 21% lobectomies or bilobecto- 
mies, and 3% pneumonectomies. Two hundred 
three lobectomies and six pneumonectomies were 
performed through median sternotomies. Surgical 
resection included other sites, such as chest wall, 
diaphragm, pleura, lymph nodes, mediastinal or- 
gans, or liver in 9% of patients. 
On the basis of pathologic assessment, single 
metastases accounted for 46% and multiple metas- 
tases 52%. Overall, 26% had four or more metasta- 
ses, 9% (n = 457) ten or more, and 3% (n = 165) 
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Fig. 1. Overall actuarial survival after lung metastasectomy: complete resection versus incomplete 
resection. The number of patients at risk at 5, 10, and 15 years is reported at the bottom of the curve. 
twenty or more; the maximum number of lesions 
resected was 154. Multiple metastases were resected 
in 64% of sarcomas, 57% of germ cell tumors, 43% 
of epithelial tumors, and 39% of melanomas. 
In a total of 97 (2%) patients, and in 54 (1%) of 
those who underwent complete metastasectomy, 
pathologic examination did not reveal any viable 
tumor. Such cases were not included in the analyses 
concerning the number of metastases. 
Metastases to hilar or mediastinal nodes were 
found in 5% of cases, corresponding to 11% of germ 
cell tumors, 8% of melanomas, 6% of epithelial 
metastases, and only 2% of sarcomas. 
Chemotherapy was administered at the time of 
occurrence of lung metastases in 38% of patients; in 
22% before metastasectomy and in the remaining 
16% only after lung resection. The proportion of 
patients receiving chemotherapy was slightly higher 
(56%) in the group having incomplete resections 
and in patients with multiple metastases (45% vs 
29% with single metastases). 
One fifth of patients underwent multiple metas- 
tasectomies (redo surgery): 15% had two metasta- 
sectomies, 4% (183) three operations, and 1% (73) 
four or more; the maximum number of metastasec- 
tomies performed on a single patient was seven. 
The likelihood of incomplete metastasectomy was
higher in patients with nodal metastases (27% vs 
11%), as well as in patients with other resections 
(23% vs 11%). 
The information on the number of lesions detect- 
able at radiologic staging was available only for 3498 
(67%) patients: 86% of these lesions were com- 
pletely resected and 14% were unresectable; 51% of 
the patients had a single radiologic lesion and 49% 
multiple lesions. The probability of incomplete re- 
section was higher in patients with multiple lesions 
(23% vs 9%). 
Within the subset of 2988 patients who had both 
preoperative radiologic and postoperative patho- 
logic assessment of the number of lesions with 
complete metastasectomy, it was possible to esti- 
mate the accuracy of clinical staging. Overall, the 
radiologic assessment of the number of lung metas- 
tases was accurate in 61% (n = 1812) of patients, 
underestimated in 25% (n = 746), and overesti- 
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Fig. 2. Survival of patients having complete resections according to the DFI: 0 to 11 months, 12 to 35 
months, and 36 or more months. 
mated in 14%. In the group of 1854 patients who 
underwent monolateral thoracotomy, the radiologic 
accuracy was 75%, underestimation 16% and over- 
estimation in only 8%. However, in the group of 
1134 patients who had median sternotomy or bilat- 
eral thoracotomy, the number of radiologic metas- 
tases was accurate in only 37%, underestimated in 
39% and overestimated in 25%. These data under- 
line the importance of bilateral surgical staging in 
lung metastasectomy. 
Survival. The total number of perioperative 
deaths was 51, corresponding to an overall operative 
mortality of 1.0%. This figure was 2.4% (n = 15) 
after incornplete resections and 0.8% (n = 36) after 
complete metastasectomy. In the group of patients 
with resectable sions, the mortality varied accord- 
ing to the maximum resection volume, being 0.6% 
(n = 20) for sublobar esections, 1.2% (n = 12) for 
lobectomies and bilobectomies, and 3.6% (n = 4) 
for pneumonectomies. By adding to the reported 
surgical deaths 18 patients who died within 30 days 
of metastasectomy, theoverall mortality was 1.3% 
and the corresponding figure for complete resec- 
tions, 1.0%. 
Fig. 1 illustrates the overall actuarial survival up 
to 15 years (180 months) for complete and incom- 
plete metastasectomies. Thesurvival after complete 
metastasectomy was 36% at 5 years, 26% at 10 
years, and 22% at 15 years, with a median survival of 
35 months; the number of patients alive at these 
intervals was 809, 254, and 78, respectively. The 
corresponding survivals for incomplete resections 
were 13% at 5 years and 7% at 10 and 15 years, with 
a median of 15 months. In this group 35 patients 
were alive at 5 years, five at 10 years, and only one 
at 15 years. The difference was highly significant 
with a log-rank X z of 245.8 (1 dl). 
Fig. 2 illustrates the actuarial survival of complete 
resections according to the DFI. For patients with a 
DFI of 0 to 11 months, the survival was 33% at 5 
years and 27% at 10 years, with a median of 29 
months. For a DFI of 12 to 35 months, the corre- 
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Fig. 3. Survival of patients having complete resections according to the number of pathologically proved 
metastases: ingle lesions, two to three lesions, and four or more lesions. 
sponding values were 31%, 22%, and 30 months; for 
a DFI of 36 months or longer, survivals were 45%, 
29%, and 49 months, respectively. 
Fig. 3 shows the actuarial survival of complete 
resections according to the number of pathologically 
proved metastases. Patients with single metastases 
had a survival of 43% at 5 years and 31% at 10 years, 
with a median of 43 months. In the group of patients 
with two or three metastases, the survival was 34% 
at 5 years and 24% at 10 years, with a median of 31 
months. Patients with four or more metastases had a 
lower survival: 27% at 5 years and 19% at 10 years, 
with a median of 27 months. However, even in the 
group of patients who had 10 or more metastases 
resected (n -- 342), the survival reached 26% at 5 
years and 17% at 10 years, with a median of 26 
months. 
Fig. 4 illustrates the actuarial survival of complete 
resections according to the four major primary 
tumors types. Patients with germ cell tumors had by 
far the best survival (68% at 5 years and 63% at 10 
years) and melanoma the worst (21% at 5 years and 
14% at 10 years, median 19 months). The survivals 
of patients with epithelial tumors (37% at 5 years 
and 21% at 10 years, median 40 months) and 
sarcomas (31% at 5 years and 26% at 10 years, 
median 29 months) did not differ significantly when 
these two large groups were compared. However, 
there were significant differences among the specific 
histologic types of sarcoma nd the various sites of 
epithelial cancer (discussed later). The survival of all 
tumor types combined (other than germ cell and 
Wilms' tumors) was 34% at 5 years and 23% at 10 
years, with a median of 33 months (not shown). 
Patients with prior or concurrent extrapulmonary 
resections had a marginally lower survival than 
patients with only pulmonary resections (29% vs 
36% at 5 years and 21% vs 27% at 10 years; not 
shown). 
Reeurrenee. A recurrence of the disease was doc- 
umented in 53% of patients who underwent com- 
plete lung metastasectomy (Table II). Median time 
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Table II. Relapse after metastasectomy 
Epithelial Sarcoma Germ cell Melanoma 
Relapse No. % No. % No. % No. % 
All sites 917 1218 84 180 
Single intrathoracic 111 12 191 16 18 21 14 8 
Multiple intrathoracic 291 32 607 50 30 36 34 19 
Extrathoracic 515 56 420 34 36 43 132 73 
Second metastasectomy 260 28 642 53 34 40 28 16 
to recurrence was 10 months. The probability of 
relapse was higher for sarcomas and melanoma 
(64%) than for epithelial (46%) or germ cell (26%) 
tumors. However, the site of relapse was signifi- 
cantly different among the four types. In sarcomas, 
intrathoracic relapse accounted for 66% of all re- 
currences, whereas in melanoma 73% of relapses 
involved extrathoracic organs. Epithelial and germ 
cell tumors showed an intermediate pattern. Median 
time to recurrence was shorter in sarcomas than in 
epithelial tumors (8 vs 12 months). 
In accordance with the relapse pattern, the pro- 
portion of patients who underwent a second metas- 
tasectomy was higher in recurrent metastatic sarco- 
mas (53%) than in any other type. Median interval 
between the first and second metastasectomy ranged 
between 10 months for sarcomas and 17 months for 
epithelial tumors. 
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Table III. Adjusted relative risks of death* 
Relative risk 95% Confidence 
No. (RRD) interval 
DFI 
Synchronous 474 0.952 (0.820, 1.104) 
1-11 mo 909 1.401 (1.263, 1.555) 
12-23 mo 1040 1.217 (1.104, 1.343) 
24-35 mo 622 1.007 (0.892, 1.136) 
36+ mo 1416 0.637 (0.575, 0.705) 
Number 
0 47 1.034 (0.678, 1.575) 
1 2169 0.764 (0.681, 0.818) 
2 738 1.070 (0.953, 1.200) 
3 487 1.021 (0.885, 1.178) 
4 235 1.316 (1.091, 1.587) 
5 214 1.183 (0.971, 1.442) 
6 125 1.328 (1.029, 1.715) 
7 88 1.251 (0.947, 1.652) 
8-9 118 1.206 (0.932, 1.561) 
10 73 1.677 (1.262, 2.229) 
11-19 179 1.083 (0.880, 1.334) 
20+ 90 1.270 (0.935, 1.725) 
Tumor type 
Teratoma 203 0.373 (0.272, 0.510) 
Wilms' 25 0.503 (0.232, 1.088) 
Embryonal 92 0.571 (0.373, 0.829) 
Uterus 83 0.796 (0.555, 1.142) 
Bowel 645 0.831 (0.721, 0.959) 
Other bone sarcoma 223 0.965 (0.789, 1.180) 
Breast 396 1.117 (0.945, 1.320) 
Head and neck 247 0.898 (0.735, 1.096) 
Kidney 372 0.928 (0.790, 1.091) 
Osteosarcoma 734 0.990 (0.863, 1.136) 
Synovial sarcoma 174 1.026 (0.833, 1.264) 
Leiomyosarcoma 156 1.098 (0.878, 1.374) 
Other epithelial 184 1.120 (0.900, 1.393) 
Other soft sarcoma 421 1.238 (1.078, 1.422) 
Histiocytoma 186 1.150 (0.937, 1.412) 
Lung 53 1.374 (0.913, 2.067) 
Melanoma 282 2.034 (1.728, 2.394) 
*Adjusted by sex, age, DFI, number of metastases, and tumor type. RRD, 
Relative risk of death. 
The long-term outcome of patients who were 
treated by a second metastasectomy was remark- 
ably good: a 44% survival at 5 years and 29% at 
10 years, compared with 34% and 25%, respec- 
tively, for patients having had one single opera- 
tion. This is not surprising in the short term, 
inasmuch as redo surgery is generally offered to 
patients with limited pulmonary relapse and good 
general condition. However, the favorable long- 
term results suggest a real curative benefit of 
repeated salvage operations, rather than a simple 
selection effect. 
Relative risks of death and multivariate analy- 
sis. Relative risks of death and multivariate anal- 
ysis were calculated on patients who had a 
complete metastasectomy. When considered sep- 
arately, DFI, number of metastases, and tumor 
type were highly significant prognostic variables; 
age was only marginally significant, and sex was 
not significant. 
Table III illustrates the relative risks of death, 
that is, the hazard rates for each level of the variable 
relative to the rest of the population, as well as 95% 
confidence limits estimated by the Cox proportional 
hazard model. The relative risks of death for each 
variable are adjusted for all the other variables of 
interest: sex, age, DFI, number of metastases, and 
tumor type. There was a trend to poorer prognosis 
(relative risk of death > 1) associated with shorter 
DFI and greater number of metastases. As ex- 
pected, the best prognosis was observed for DFIs of 
36 months or more, single metastases, germ cell 
tumors, and Wilms' tumors. As far as tumor type 
was concerned, melanoma had clearly the worst 
prognosis. 
When considered simultaneously, primary tumor 
type, DFI, and number of metastases merged as 
highly significant prognostic factors. In particular, 
germ cell and Wilms' tumors howed the best prog- 
nosis (relative risk [RR] = 0.4) and melanoma the 
worst prognosis (RR = 2.1); the value of 36 months 
or more seemed to be the best DFI cutoff to identify 
a large group of patients with a clearly bettet 
prognosis (RR = 0.6). Similarly, single versus mul- 
tiple metastases seemed to be the best way to group 
the number of lesions without losing too rauch 
information, single metastases having a clearly bet- 
ter prognosis (RR -- 0.7). 
Prognostic grouping. This model was used to 
construct a system of prognostic groupings that 
could take into account all the relevant prognostic 
factors simultaneously. Germ cell and Wilms' tu- 
mors were not included in this system of prognostic 
grouping because of their peculiar clinical features 
and, particularly, the different role of metastasec- 
tomy after effective chemotherapy. 
To build a prognostic grouping that would be 
simple, discriminant, and valid in different umor 
types (other than germ cell and Wilms' tumors), we 
used three parameters of prognostic significance: 
resectability, DFI, and number of metastases. 
Among patients with resectable l sions, a DFI of 
less than 36 months and multiple metastases were 
seen to be independent risk factors. Four clearly 
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Fig. 5. Survival of the four prognostic groups: resectable, no risk factors (DFI -> 36 months and single 
metastasis); resectable, one risk factor (DFI < 36 months or multiple metastases); resectable, two risk 
factors (DFI < 36 months and multiple metastases), and unresectable. Germ cell and Wilms' tumors were 
excluded. 
distinct prognostic groups could thus be identi- 
fied: 
Group I: Resectable, no risk factors (DFI -> 36 
months, and single metastasis) 
Group II: Resectable, one risk factor (DFI < 36 
months or multiple metastases) 
Group III: Resectable, two risk factors (DFI < 36 
months and multiple metastases) 
Group IV: Unresectable 
Fig. 5 shows the actuarial survival of the four 
prognostic groups. The difference among the curves 
was massively significant with a log-rank 9( 2 of 328.2 
(3 dl). Median survival was 61 months for group I, 
34 months for group II, 24 months for group III, and 
14 months for group IV. 
The discriminant power of this prognostic group- 
ing was tested on different primary tumors (curves 
not shown) and proved to be highly significant in 
each specific tumor type. The log-rank 9( 2 (3 dl) was 
131.8 for epithelial tumors, 118.8 for bone sarcomas, 
77.4 for soft tissue sarcomas, and 29.6 for melano- 
mas. 
Discussion 
The project of the International Registry of Lung 
Metastases had identified ~n the initial research 
protocol a few clear objectives: to gather the expe- 
rience of leading centers of thoracic surgery in the 
world with outstanding tradition in cancer esearch, 
to perform a homogeneous evaluation of the results 
of lung metastasectomy with multifactorial nalysis 
and proper adjustment for relevant clinical features, 
to set up the basis for a system of classification and 
staging of lung metastases applicable to the various 
histologic types, and to promote prospective clinical 
trials on specific areas of uncertainty (optimal sur- 
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gery, neoadjuvant and adjuvant chemotherapy) for 
the various diseases. Most of these targets have been 
reached. 
The excellence of surgical centers participating in
this project has made it possible not only to collect 
a large number of cases and the broadest spectrum 
of primary diseases, but also to provide an extensive 
period of observation. In fact, our analyses of sur- 
vival and long-term prognosis are based on a con- 
siderable number of patients alive at 10 to 15 years. 
The results of this International Registry of Lung 
Metastases confirm that metastasectomy is a poten- 
tially curative treatment that can be administered 
safely with low mortality. In keeping with general 
principles of surgical oncology, complete removal of 
all metastatic deposits is associated with long-term 
survival. Our data suggest that radiologic staging is 
inaccurate in a large proportion of cases and that 
intraoperative exploration by an experienced sur- 
geon is required to optimize resection of all metas- 
tases. 18-22 Thorough intraoperative staging is there- 
fore required to identify and resect all 
metastases. 23-26 In this respect, video-assisted thora- 
coscopy cannot provide optimal intraoperative iden- 
tification of pulmonary metastases, particularly 
when more than one lesion is identified in the preop- 
erative period. Our results also suggest that multiple 
metastasectomies may be required to achieve perma- 
nent cure, and that repeated salvage surgery can be 
safe and effective over the long termY' 28 
The role of lung metastasectomy is less clear in 
tumors such as breast cancer and melanoma nd 
needs to be bettet defined by future prospective 
studies. Other areas of uncertainty hat may require 
prospective randomized trials are the efficacy of 
surgical screening of occult contralateral metastases 
by median sternotomy (of bilateral thoracotomy) in 
tumors other than sarcomas, as well as the contri- 
bution of induction/adjuvant chemotherapy in spe- 
cific tumor types. 
The present proposal of four prognostic groups, 
based on three easily available clinical parameters, 
represents a preliminary attempt at achieving a 
simple system of classification. Our present data 
indicate that this system is discriminant in very 
different umor types, but further analyses of the 
Registry data are planned to confirm its validity. On 
the other hand, the Registry could not assess the 
role of potential tumor-specific prognostic factors 
such as estrogen receptors in breast cancer, histo- 
logic grading in sarcomas, 29or carcinoembryonic 
antigen in colorectal cancer. 3° 
An important problem that remains completely 
undefined is the applicability of salvage surgery in 
the various diseases. In fact, the proportion of all 
cases of lung metastases that are amenable to 
salvage surgery with curative intent varies enor- 
mously among the different umors, ranging from 
over 50% in osteosarcomas 9 and other pediatric 
tumors to rar less than 1% in most epithelial can- 
cers. 
Such questions could not be addressed within the 
present project because itwas impossible to identify 
a proper denominator, but they may be considered 
in future developments of the Registry. 
The present database is available and running in 
the various centers for the purposes of updating and 
follow-up of retrospective cases. In the meantime, a 
new version of the database is being developed to 
improve the scientific quality of data in the future, 
to facilitate prospective accrual of new cases, and to 
promote the expansion of the International Registry 
to new members. 
Members of the International Registry of Lung 
Metastases 
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The Netherlands: Albert N. van Geel, Dr. Daniel den 
Hoed Cancer Center, Rotterdam; Belgium: Matteo Cap- 
pello and Pierre Rocmans, Hôpital Erasme, Brussels; 
Poland: Andrezej Pietraszek and Maria Sklodowska, War- 
saw; Italy: Stefano Andreani, Matteo Incarbone, Gianni 
Ravasi, and Luca Tavecchio, Istituto Nazionale Tumori, 
Milano; Vincenzo Ambrogi and Costante Ricci, Univer- 
sitä La Sapienza; Tommaso Mineo, Universitä Tor Ver- 
gata, Roma; Giuliano Maggi, Ospedale Le Molinette 
Universitä di Torino; Antonio Briccoli, Roberta Gelmini, 
and Afsmin Heidari, Patologia Chirurgica Universitä di 
Modena; Natalino Guernelli, Ospedale S. Orsola, Bolo- 
gna; Vanni Beltrami, Universitä "G. D'Annunzio," Chieti; 
United Stares: Manjit S. Bains, Michael E. Burt, Robert J. 
Ginsberg, Nael Martini, Patricia M. McCormack, and 
Valerie W. Rusch, Memorial Sloan Kettering, New York; 
Joe B. Putnam, Jr., and Jack Roth, The University of 
Texas M. D. Anderson Cancer Center, Houston; Carmack 
Holmes, University of California (UCLA), Los Angeles; 
Harvey Pass and Barbara Temeck, National Cancer Insti- 
tute, Bethesda; Canada: Michael Johnston, Mount Sinai 
Hospital, Toronto. 
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Discussion 
Dr. Valerie W. Rusch (New York, N.Y). The benefit of 
pulmonary metastasectomy is still questioned by some 
physicians, particularly nonsurgeons, because patients are 
frequently offered this treatment on a highly individual- 
ized basis, and the prognosis of such patients without 
surgical resection is still not fully known. Although it is 
unlikely that the benefit of surgi¢al resection compared 
with supportive care alone could ever be defined in a 
randomized manner prospectively, analysis of this large, 
carefully developed multiinstitutional registry ¢onfirms 
that patients whose tumors are unlikely to respond to 
systemic therapy orten survive long term after pulmonary 
metastase¢tomy. 
Several important features of this study include the 
confirmation of the prognostic importan¢e of the number 
of metastases, the DFI, tumor histologic type, complete 
resection, and espe¢ially the documentation f long-term 
survival at 10 and even 15 years after resection. It is 
striking that long-term survival was seen in a small pro- 
portion of patients to whom we often hesitate to offer 
resection, those who have four or eren as many as ten 
metastases. 
I have a few questions for Dr. Pastorino. A total of 239 
patients were reported as having diseased N1 or N2 nodes. 
Could you tell us how many patients actually had com- 
plete nodal sampling and what percentage of these do the 
239 patients represent? Is su~¢ient information available 
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to make a statistically valid statement about the prognos- 
tic importance of nodal disease? 
Second, you suggested that all patients should have 
both lungs surgically examined because of the diagnostic 
inaccuracy of current imaging techniques. However, the 
data suggest hat the diagnostic accuracy of computed 
tomography is especially poor in patients who are already 
known to have multiple bilateral metastases, and certainly 
bilateral exploration i  all patients is not standard care in 
many centers. One way to clarify this issue would be to 
analyze the patients who underwent unilateral thoracot- 
omy and to tell us how many of those have a quick relapse, 
say, within 6 to 12 months, in the contralateral lung. 
Third, a particular dilemma is when to perform redo 
operations for recurrent metastases. How many of the 
patients who had multiple metastasectomies survived 5 
and 10 years? Is there a point at which redo operations 
become inappropriate? 
Fourth, in the manuscript the discriminant power of the 
algorithm for prognostic grouping, which you noted at the 
end of the presentation, is noted to be lowest for mela- 
noma. Could you comment on this? Are there prognostic 
groups for which the survivals either for melanoma or 
other histologic types are so poor that pulmonary metas- 
tasectomy is simply not worth considering? 
Finally, you note in the manuscript that patients with 
prior or concurrent resection of extrapulmonary metasta- 
ses had a marginally lower survival. How many patients 
were actually in this category? Are there circumstances in 
which prior or concurrent resections, ay, a liver resection, 
then a lung resection, are either clearly appropriate or of 
no benefit? 
Dr. Pastorino. Thank you, Dr. Rusch, for these very 
important questions. 
Nodal disease was documented in about 5% of our 
patients, but we could not discriminate between patients 
having had a full nodal dissection and patients who had 
just a sampling or diagnostic assessment. We can try to 
estimate this value in terms of percent of patients re- 
ported as having complete resection and assume that 
under these circumstances the positive nodal status was 
based on complete dissection. However, nodal dissection 
in metastatic disease is only applied at the discretion of 
the surgeon, and we cannot provide this information 
reliably. What I can tell you is that in the whole series the 
difference in long-term survival was not significant. How- 
ever, the relevance of nodal metastases has to be explored 
within each separate cell type. In fact, the prognosis of 
diseased lymph nodes is completely different for germ cell 
tumors than for melanomas. I suspect that when we adjust 
for the primary tumor this factor may become significant. 
It is difficult to ässess the value of bilateral surgical 
screening with a retrospective analysis. We will certainly 
try to evaluate the frequency of early relapses in patients 
who underwent sternotomy compared with those treated 
by thoracotomy. However, I believe that this question 
should be addressed by a prospective randomized trial in 
properly selected patients. 
The group of patients with multiple metastasectomies 
in our experience had a very good survival. The 5-year 
survival was actually higher in patients having undergone 
redo surgery: 44% compared with 34% for patients who 
had only one metastasectomy. This is due in part to the 
patient selection, because to get the second metastasec- 
tomy, the patient has to have a limited recurrence, have 
good performance status, and probably be comparatively 
young. However, I must reiterate that those patients who 
received a second metastasectomy had a good long-term 
survival. 
The prognosis of melanoma is dismal, but there are 
patients who can be cured. I could not show these data, 
but within out system of prognostic grouping, none of the 
patients classified in group III or IV survived. Patients 
classified in group I had significantly better survival sta- 
tistics than patients in group II, but both groups had 
long-term survivors. So there is a curative space for 
metastasectomy in melanoma, but patients who have two 
concurrent risk factors probably should be excluded. 
As far as other resections are concerned, we could not 
demonstrate a prognostic impact of such condition in the 
whole population. However, nodal status has to be exam- 
ined within each individual tumor because the biology of 
the various tumors is different. For example, in colon 
cancer the association of liver metastasis, provided that 
the resection of all metastatic deposits in the liver is 
complete, does not confer a poorer life expectancy. By 
contrast, inasmuch as liver metastasis tends to occur 
earlier, patients with previous liver metastasis are more 
selected, and when they require lung metastasectomy they 
usually have a good prognosis. Again, this will be the 
subject of further analyses. 
Dr. Stefano Nazari (Pavia, Italy). I wonder whether the 
good results in this field could allow us to change our 
minds about the treatment of primary cancer with lung 
metastasis at the time of the primary cure. For example, 
may surgery be an option in a patient with lung cancer and 
contralateral metastasis, who now is considered not suit- 
able for surgery? 
Dr. Pastorino. For certain primary tumors, this is 
certainly true. In sarcomas, particularly osteosarcoma, 
metastasectomy for patients with synchronous metastases 
has probably the same chance of success as for patients 
with a long disease-free survival. In other words, synchro- 
nous metastases in sarcomas may not represent a more 
aggressive disease and certainly are suitable for curative 
metastasectomy, provided that the other criteria are sat- 
isfied. This is not true for other tumors. Particularly in 
lung cancer, I do not see any place for curative resection 
of synchronous metastases and primary tumors. I could 
not provide the data for each primary tumor, but in this 
series metastasectomy for lung cancer has a poor progno- 
sis, similar to that of melanoma. It may be applicable to a 
tiny minority of patients, if any. Furthermore, in this 
subset there is a big problem of bias and confusion 
between new primary cancer and metastases. In other 
words, you never know when you resect one single pul- 
monary lesion whether you are really dealing with a 
metastasis or a new primary tumor of the lung. 
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Append ix  1. Number of cases by center 
Country Hospital No. of patients 
England 
France 
Germany 
The Netherlands 
Belgium 
Poland 
Italy 
United States 
Canada 
Royal Brompton Hospital (RBH), London 
Centre Marie Lannelongue (CCML), Paris 
Hopital Porte de Choisy, Paris 
Rohrbach Clinic, Heidelberg 
Thoraxchirurgie, Gerlingen 
Daniel den Hoed Cancer Center, Rotterdam 
Hopital Erasme, ULB, Brussels 
Maria Sklodowska, Warsaw 
Istituto Nazionale Tumori (INT), Milano 
Universitä La Sapienza nd Tor Vergata, Roma 
Ospedale Le Molinette Universitä di Torino 
Patologia Chirurgica di Modena and Ospedale S. Orsola, Bologna 
Universitä "G. D'Annunzio", Chieti 
Memorial Sloan Kettering Cancer Center (MSKCC), New York 
The University of Texas M. D. Anderson Cancer Center 
(MDACC), Houston 
University of California (UCLA), Los Angeles 
National Cancer Institute (NCI), Bethesda 
Mount Sinai Hospital, Toronto 
289 
184 
561 
152 
528 
89 
41 
125 
548 
119 
136 
302 
62 
1075 
469 
86 
338 
102 
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